Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

Cost Effectiveness and Resource Allocation

Volumn 7, Issue , 2009, Pages

  Furiak, Nicolas M ^a   Ascher Svanum, Haya ^b   Klein, Robert W ^a   Smolen, Lee J ^a   Lawson, Anthony H ^b   Conley, Robert R ^c   Culler, Steven D ^d  

^a Medical Decision Modeling Inc   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c Lilly USA   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETES MELLITUS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG PREFERENCE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG UTILIZATION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MONTE CARLO METHOD; PATIENT COMPLIANCE; QUALITY ADJUSTED LIFE YEAR; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SIDE EFFECT; SIMULATION; SUICIDE; UNITED STATES; WEIGHT GAIN;

EID: 65649130874     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-7-4     Document Type: Article

References (106)

1. Wyatt RJ Henter I Leary MC Taylor E An economic evaluation of schizophrenia - 1991 Soc Psychiatry Psychiatr Epidemiol 1995, 30:196-205. 7482004
2. Rupp A Keith SJ The costs of schizophrenia. Assessing the burden Psychiatr Clin North Am 1993, 16:413-423. 8332569
3. Wu EQ Birnbaum HG Shi L Ball DE Kessler RC Moulis M Aggarwal J The economic burden of schizophrenia in the United States in 2002 J Clin Psychiatry 2005, 66:1122-1129. 16187769
4. Practice Guidelines for the Treatment of Patients with Schizophrenia Am J Psychiatry Second 2004, 161:1-56. 10.1176/appi.ajp.161.1.1
5. Cramer JA Rosenheck R Compliance with medication regimens for mental and physical disorders Psychiatr Serv 1998, 49:196-201. 9575004
6. Herz MI Glazer WM Mostert MA Sheard MA Szymanski HV Hafez H Mirza M Vana J Intermittent vs maintenance medication in schizophrenia. Two-year results Arch Gen Psychiatry 1991, 48:333-339. 1672588
7. Weiden PJ Kozma C Grogg A Locklear J Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia Psychiatr Serv 2004, 55:886-891. 10.1176/appi.ps.55.8.886 15292538
8. Mojtabai R Lavelle J Gibson PJ Bromet EJ Atypical antipsychotics in first admission schizophrenia: Medication continuation and outcomes Schizophr Bull 2003, 29:519-530. 14609245
9. Svarstad BL Shireman TI Sweeney JK Using drug claims data to assess the relationship of medication adherence with hospitalization and costs Psychiatr Serv 2001, 52:805-811. 10.1176/appi.ps.52.6.805 11376229
10. Thieda P Beard S Richter A Kane J An economic review of compliance with medication therapy in the treatment of schizophrenia Psychiatr Serv 2003, 54:508-516. 10.1176/appi.ps.54.4.508 12663838
11. Valenstein M Copeland LA Blow FC McCarthy JF Zeber JE Gillon L Bingham CR Stavenger T Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission Med Care 2002, 40:630-639. 10.1097/00005650-200208000-00002 12187177
12. Ascher-Svanum H Faries DE Zhu B Ernst FR Swartz MS Swanson JW Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care J Clin Psychiatry 2006, 67:453-460. 16649833
13. Sun SX Liu GG Christensen DB Fu AZ Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States Curr Med Res Opin 2007, 23:2305-2312. 10.1185/030079907X226050 17697454
14. Law MR Soumerai SB Ross-Degnan D Adams AS A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia J Clin Psychiatry 2008, 69:47-53. 18312037
15. Weiden PJ Olfson M Cost of relapse in schizophrenia Schizophr Bull 1995, 21:419-429. 7481573
16. Gilmer TP Dolder CR Lacro JP Folsom DP Lindamer L Garcia P Jeste DV Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia Am J Psychiatry 2004, 161:692-699. 10.1176/appi.ajp.161.4.692 15056516
17. Rosenheck RA Leslie DL Sindelar J Miller EA Lin H Stroup TS McEvoy J Davis SM Keefe RS Swartz M Perkins DO Hsiao JK Lieberman J CATIE Study Investigators Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia Am J Psychiatry 2006, 163:2080-2089. 10.1176/ appi.ajp.163.12.2080 17151158
18. Edwards NC Locklear JC Rupnow MF Diamond RJ Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA Pharmacoeconomics 2005, 23(Suppl 1):75-89. 10.2165/00019053-200523001-00007 16416763
19. Farahati F Boucher M Moulton K Williams R Herrmann N Silverman M Skidmore B Overview of atypical antipsychotic monotherapy for schizophrenia: Clinical review and economic evaluation of first year of treatment [Technology overview number 32] Ottawa: Canadian Agency for Drugs and Technologies in Health 2007.
20. Keith SJ Kane JM Partial compliance and patient consequences in schizophrenia: Our patients can do better J Clin Psychiatry 2003, 64:1308-1315. 14658944
21. Valenstein M Blow FC Copeland LA McCarthy JF Zeber JE Gillon L Bingham CR Stavenger T Poor antipsychotic adherence among patients with schizophrenia: Medication and patient factors Schizophr Bull 2004, 30:255-264. 15279044
22. Ascher-Svanum H Zhu B Faries DE Furiak NM Montgomery W Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia BMC Res Notes 2009, 2:6. 2628922 19138402 10.1186/1756-0500-2-6
23. Lieberman JA Stroup TS McEvoy JP Swartz MS Rosenheck RA Perkins DO Keefe RS Davis SM Davis CE Lebowitz BD Severe J Hsiao JK Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 2005, 353:1209-1223. 10.1056/NEJMoa051688 16172203
24. Stroup TS Lieberman JA McEvoy JP Swartz MS Davis SM Rosenheck RA Perkins DO Keefe RS Davis CE Severe J Hsiao JK CATIE Investigators Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic Am J Psychiatry 2006, 163:611-622. 10.1176/ appi.ajp.163.4.611 16585435
25. McEvoy JP Lieberman JA Stroup TS Davis SM Meltzer HY Rosenheck RA Swartz MS Perkins DO Keefe RS Davis CE Severe J Hsiao JK CATIE Investigators Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment Am J Psychiatry 2006, 163:600-610. 10.1176/appi.ajp.163.4.600 16585434
26. Diaz E Neuse E Sullivan MC Pearsall HR Woods SW Adherence to conventional and atypical antipsychotics after hospital discharge J Clin Psychiatry 2004, 65:354-360. 15096075
27. García-Cabeza I Gómez JC Sacristán JA Edgell E González de Chavez M Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study) BMC Psychiatry 2001, 1:7. 65550 11835695 10.1186/1471-244X-1-7
28. Gibson PJ Damler R Jackson EA Wilder T Ramsey JL The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population Value Health 2004, 7:22-35. 10.1111/ j.1524-4733.2004.71272.x 14720128
29. Opolka JL Rascati KL Brown CM Gibson PJ Role of ethnicity in predicting antipsychotic medication adherence Ann Pharmacother 2003, 37:625-630. 10.1345/aph.1C321 12708934
30. Rascati KL Johnsrud MT Crismon ML Lage MJ Barber BL Olanzapine versus risperidone in the treatment of schizophrenia: A comparison of costs among Texas Medicaid recipients Pharmacoeconomics 2003, 21:683-697. 10.2165/00019053-200321100-00001 12828491
31. Ascher-Svanum H Zhu B Faries DE Lacro JP Dolder CR Peng X Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia Pat Pref Adherence 2008, 2:67-77.
32. Zhao Z A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia Manag Care Interface 2002, 15:75-81. 11875967
33. Bagnall AM Jones L Ginnelly L Lewis R Glanville J Gilbody S Davies L Torgerson D Kleijnen J A systematic review of atypical antipsychotic drugs in schizophrenia Health Technol Assess 2003, 7:1-193. http://www.ncchta.org/project.asp?PjtId=1235 Health Technology Assessment (HTA) on behalf of the National Institute for Clinical Excellence (NICE) in the UK. 12925268
34. Breier A Berg PH Thakore JH Naber D Gattaz WF Cavazzoni P Walker DJ Roychowdhury SM Kane JM Olanzapine versus ziprasidone: Results of a 28-week double-blind study in patients with schizophrenia Am J Psychiatry 2005, 162:1879-1887. 10.1176/appi.ajp.162.10.1879 16199834
35. Cooper D Moisan J Grégoire JP Adherence to atypical antipsychotic treatment among newly treated patients: A population-based study in schizophrenia J Clin Psychiatry 2007, 68:818-825. 17592904
36. Dossenbach M Erol A el Mahfoud Kessaci M Shaheen MO Sunbol MM Boland J Hodge A O'Halloran RA Bitter I IC-SOHO Study Group Effectiveness of antipsychotic treatments for schizophrenia: Interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol J Clin Psychiatry 2004, 65:312-321. 15096069
37. Gilbody SM Bagnall AM Duggan L Tuunainen A Risperidone versus other atypical antipsychotic medication for schizophrenia Cochrane Database Syst Rev 2000, 3:CD002306. 10908551
38. Haro JM Suarez D Novick D Brown J Usall J Naber D SOHO Study Group Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results Eur Neuropsychopharmacol 2007, 17:235-244. 10.1016/j.euroneuro.2006.09.005 17137759
39. Kinon BJ Lipkovich I Edwards SB Adams DH Ascher-Svanum H Siris SG A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms J Clin Psychopharmacol 2006, 26:157-162. 10.1097/01.jcp.0000204137.82298.06 16633144
40. Kinon BJ Noordsy DL Liu-Seifert H Gulliver AH Ascher-Svanum H Kollack-Walker S Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning J Clin Psychopharmacol 2006, 26:453-461. 10.1097/ 01.jcp.0000236658.16286.25 16974184
41. Mudge NAC Davey PJ Coleman KA Montgomery WS Croker VS Castle DJ A comparison of olanzapine versus risperidone for the treatment of schizophrenia - a meta analysis of randomized clinical trials Int J Psychiatr Clin Pract 2005, 9:3-15. 10.1080/13651500510014783
42. Mullins CD Obeidat NA Cuffel BJ Naradzay J Loebel AD Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia Schizophr Res 2008, 98:8-15. 10.1016/j.schres.2007.04.035 17596914
43. Pelagotti F Santarlasci B Vacca F Trippoli S Messori A Dropout rates with olanzapine or risperidone: A multi-centre observational study Eur J Clin Pharmacol 2004, 59:905-909. 10.1007/s00228-003-0705-0 14685800
44. Fleischhacker WW McQuade RD Marcus RN Archibald D Swanink R Carson WH A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia Biol Psychiatry 2009, 65:510-507. 18986646 10.1016/j.biopsych.2008.07.033
45. Ren XS Kazis LE Lee AF Hamed A Huang YH Cunningham F Miller DR Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia J Clin Pharm Ther 2002, 27:441-451. 10.1046/j.1365-2710.2002.00443.x 12472984
46. Santarlasci B Messori A Clinical trial response and dropout rates with olanzapine versus risperidone Ann Pharmacother 2003, 37:556-563. 10.1345/ aph.1C291 12659615
47. Simpson GM Glick ID Weiden PJ Romano SJ Siu CO Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder Am J Psychiatry 2004, 161:1837-1847. 10.1176/ appi.ajp.161.10.1837 15465981
48. Strom B Faich G Eng S Reynolds R D'Agostino R Sr Ruskin J Kane J Comparative Mortality Associated with Ziprasidone vs. Olanzapine in Real-World Use: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). [Abstract] Schizophr Res 2008, 98(Suppl):160-161. 10.1016/ j.schres.2007.12.377
49. Tunis SL Faries DE Nyhuis AW Kinon BJ Ascher-Svanum H Aquila R Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: Results from a randomized, open-label, 1-year trial Value Health 2006, 9:77-89. 10.1111/j.1524-4733.2006.00083.x 16626411
50. Ciudad A Haro JM Alonso J Bousoño M Suárez D Novick D Gilaberte I The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain Eur Psychiatry 2008, 23:1-7. 10.1016/ j.eurpsy.2007.09.008 18023154
51. Bitter I Treuer T Dyachkova Y Martenyi F McBride M Ungvari GS Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study Eur Neuropsychopharmacol 2008, 18:170-180. 10.1016/j.euroneuro.2007.08.001 17884390
52. Liu-Seifert H Adams DH Kinon BJ Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: A pooled post-hoc analysis of four atypical antipsychotic drugs BMC Med 2005, 3:21. 1327673 16375765 10.1186/1741-7015-3-21
53. Liu-Seifert H Houston JP Adams DH Kinon BJ Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia J Clin Psychopharmacol 2007, 27:392-394. 10.1097/ 01.jcp.0000264986.32733.df 17632224
54. Perkins DO Gu H Weiden PJ McEvoy JP Hamer RM Lieberman JA Comparison of Atypicals in First Episode study group Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: A randomized, double-blind, flexible-dose, multicenter study J Clin Psychiatry 2008, 69:106-113. 18312044
55. Karow A Czekalla J Dittmann RW Schacht A Wagner T Lambert M Schimmelmann BG Naber D Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia J Clin Psychiatry 2007, 68:75-80. 17284133
56. Rosenheck R Perlick D Bingham S Liu-Mares W Collins J Warren S Leslie D Allan E Campbell EC Caroff S Corwin J Davis L Douyon R Dunn L Evans D Frecska E Grabowski J Graeber D Herz L Kwon K Lawson W Mena F Sheikh J Smelson D Smith-Gamble V Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: A randomized controlled trial JAMA 2003, 290:2693-2702. 10.1001/ jama.290.20.2693 14645311
57. Davies LM Lewis S Jones PB Barnes TR Gaughran F Hayhurst K Markwick A Lloyd H CUtLASS team Cost-effectiveness of first- v. second-generation antipsychotic drugs: Results from a randomised controlled trial in schizophrenia responding poorly to previous therapy Br J Psychiatry 2007, 191:14-22. 10.1192/bjp.bp.106.028654 17602120
58. Beard SM Maciver F Clouth J Rüther E A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany Eur J Health Econ 2006, 7:165-172. 10.1007/ s10198-006-0347-0 16896764
59. Kane JM Leucht S Carpenter D Docherty JP Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: Methods, commentary, and summary J Clin Psychiatry 2003, 64(Suppl 12):5-19. 14640142
60. Siris SG Suide and schizophrenia J Psychopharmacol 2001, 15:127-135. 10.1177/026988110101500209 11448086
61. Bettonvil BW Kleijnen JP Searching for important factors in simulation models with many factors: Sequential bifurcation Eur J Operational Res 1997, 96:180-194. 10.1016/S0377-2217(96)00156-7
62. Ahn J McCombs JS Jung C Croudace TJ McDonnell D Ascher-Svanum H Edgell ET Shi L Classifying patients by antipsychotic adherence patterns using latent class analysis: Characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program Value Health 2008, 11:48-56. 18237360
63. Ascher-Svanum H Zhu B Faries D Landbloom R Swartz M Swanson J Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia BMC Psychiatry 2006, 6:8. 1402287 16504026 10.1186/1471-244X-6-8
64. Ascher-Svanum H Zhu B Faries D Ernst FR A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia Ann Gen Hosp Psychiatry 2004, 3:11. 428579 15175112 10.1186/1475-2832-3-11
65. Olfson M Mechanic D Hansell S Boyer CA Walkup J Weiden PJ Predicting medication noncompliance after hospital discharge among patients with schizophrenia Psychiatr Serv 2000, 51:216-222. 10.1176/appi.ps.51.2.216 10655006
66. Tiihonen J Walhbeck K Lönnqvist J Klaukka T Ioannidis JP Volavka J Haukka J Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: Observational follow-up study BMJ 2006, 333:224. 1523484 16825203 10.1136/bmj.38881.382755.2F
67. Carlson CD Cavazzoni PA Berg PH Wei H Beasley CM Kane JM An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: Comparisons with placebo, haloperidol, risperidone, or clozapine J Clin Psychiatry 2003, 64:898-906. 12927004
68. Fleischhacker WW McQuade RD Marcus RN Archibald D Swanink R Carson WH A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia Biol Psychiatry 2009, 65:510-517. 10.1016/j.biopsych.2008.07.033 18986646
69. Lambert BL Cunningham FE Miller DR Dalack GW Hur K Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia Am J Epidemiol 2006, 164:672-681. 10.1093/aje/kwj289 16943266
70. Lambert BL Chang KY Tafesse E Carson W Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia J Clin Psychopharmacol 2005, 25:12-18. 10.1097/ 01.jcp.0000150224.38630.ae 15643095
71. Olfson M Marcus SC Corey-Lisle P Tuomari AV Hines P L'Italien GJ Hyperlipidemia following treatment with antipsychotic medications Am J Psychiatry 2006, 163:1821-1825. 10.1176/appi.ajp.163.10.1821 17012695
72. Anderson KM Odell PM Wilson PW Kannel WB Cardiovascular disease risk profiles Am Heart J 1991, 121:293-298. 10.1016/0002-8703(91)90861-B 1985385
73. Goff DC Sullivan LM McEvoy JP Meyer JM Nasrallah HA Daumit GL Lamberti S D'Agostino RB Stroup TS Davis S Lieberman JA A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls Schizophr Res 2005, 80:45-53. 10.1016/ j.schres.2005.08.010 16198088
74. Haffner SM Relationship of metabolic risk factors and development of cardiovascular disease and diabetes Obesity (Silver Spring) 2006, 14(Suppl 3):S121-S127. 10.1038/oby.2006.291
75. Suzuki T Uchida H Watanabe K Nomura K Takeuchi H Tomita M Tsunoda K Nio S Den R Manki H Tanabe A Yagi G Kashima H How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone? - A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting Psychopharmacology (Berl) 2007, 195:285-295. 10.1007/ s00213-007-0872-2 17701027
76. Lenert LA Sturley AP Rapaport MH Chavez S Mohr PE Rupnow M Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores Schizophr Res 2004, 71:155-165. 10.1016/j.schres.2003.10.010 15374583
77. Conley RR Mahmoud R A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder Am J Psychiatry 2001, 158:765-774. 10.1176/appi.ajp.158.5.765 11329400
78. Kern RS Green MF Cornblatt BA Owen JR McQuade RD Carson WH Ali M Marcus R The neurocognitive effects of aripiprazole: An open-label comparison with olanzapine Psychopharmacology (Berl) 2006, 187:312-320. 10.1007/ s00213-006-0428-x 16810506
79. Analysource Data. AWP/NWP cost of antipsychotics accessed at Analysource.com on 01-30-2007
80. drugstore.com http://www.drugstore.com/pharmacy/prices/drugprice.asp?ndc= 00006074954&trx=1Z5006;http://www.drugstore.com/pharmacy/prices/ drugprice.asp?ndc=00378654091&trx=1Z5006 Accessed October, 2007.
81. Marder SR Essock SM Miller AL Buchanan RW Casey DE Davis JM Kane JM Lieberman JA Schooler NR Covell N Stroup S Weissman EM Wirshing DA Hall CS Pogach L Pi-Sunyer X Bigger JT Jr Friedman A Kleinberg D Yevich SJ Davis B Shon S Physical health monitoring of patients with schizophrenia Am J Psychiatry 2004, 161:1334-1349. 10.1176/appi.ajp.161.8.1334 15285957
82. HCUP Nationwide Inpatient Sample (NIS) Healthcare Cost and Utilization Project (HCUP). Agency for healthcare Research and Quality, Rockville, MD 2004. http://hcupnet.ahrq.gov/HCUPnet.jsp
83. Bureau of Labor Statistics. Consumer Price Index - Medical Services Component 2007. http://data.bls.gov/cgi-bin/surveymost?cu
84. Leslie DL Rosenheck RA Pharmacotherapy and health care costs among patients with schizophrenia and newly diagnosed diabetes Psychiatr Serv 2005, 56:803-809. 10.1176/appi.ps.56.7.803 16020811
85. Grosse SD Teutsch SM Haddix AC Lessons from cost-effectiveness research for United States public health policy Annu Rev Public Health 2007, 28:365-391. 10.1146/annurev.publhealth.28.021406.144046 17222080
86. Tran PV Hamilton SH Kuntz AJ Potvin JH Andersen SW Beasley C Jr Tollefson GD Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders J Clin Psychopharmacol 1997, 7:407-418. 10.1097/00004714-199710000-00010 9315992
87. Keefe RS Young CA Rock SL Purdon SE Gold JM Breier A HGGN Study Group One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia Schizophr Res 2006, 81:1-15. 10.1016/j.schres.2005.07.038 16202565
88. Treuer T Gal G Raducan L Rudzianskiene S Szulc A Pecenak J Logozar Perkovic D Leadbetter J O'Mahoney J The clinical status of neuroleptic naïve patients with schizophrenia following monotherapy with olanzapine, risperidone or typical antipsychotics: A 12-month analysis Eur Neuropsychopharmacol 2004, 14:S255-S256. 10.1016/ S0924-977X(04)80274-8
89. Faries D Ascher-Svanum H Zhu B Psychiatric hospitalizations and violent behaviors in the long-term naturalistic treatment of schizophrenia patients with olanzapine or quetiapine [abstract] Schizophr Bull 2005, 31:541.
90. Haro JM Novick D Suarez D Alonso J Lépine JP Ratcliffe M SOHO Study Group Remission and relapse in the outpatient care of schizophrenia: Three-year results from the Schizophrenia Outpatient Health Outcomes study J Clin Psychopharmacol 2006, 26:571-578. 10.1097/ 01.jcp.0000246215.49271.b8 17110813
91. Yu AP Atanasov P Birnbaum H Ben-Hamadi R Philips G Annual healthcare costs of schizophrenia patients treated with olanzapine vs. quetiapine in a Medicaid population: An application of propensity score method with optimal matching algorithm [abstract] American Psychiatric Association annual meeting; San Diego 2007.
92. Leucht S Komossa K Rummel-Kluge C Corves C Hunger H Schmid F Asenjo Lobos CA Schwarz S Davis JM A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia Am J Psychiatry 2009, 166:152-163. 10.1176/appi.ajp.2008.08030368 19015230
93. Obradovic M Mrhar A Kos M Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia [abstract] Int J Clin Pract 2007, 61:1979-1988. 10.1111/j.1742-1241.2007.01431.x 17997804
94. Leeuwenkamp O Morlock R Bell C Brogan A Mauskopf J Costs and outcomes of atypical antipsychotics for the treatment of acute schizophrenia [abstract] Value Health 2008, 98:167.
95. Windmeijer F Kontodimas S Knapp M Brown J Haro JM Methodological approach for assessing the cost-effectiveness of treatments using longitudinal observational data: The SOHO study Int J Technol Assess Health Care 2006, 22:460-468. 10.1017/S0266462306051385 16984679
96. Edgell ET Andersen SW Johnstone BM Dulisse B Revicki D Breier A Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia Pharmacoeconomics 2000, 18:567-579. 10.2165/00019053-200018060-00004 11227395
97. Alexyeva I Mauskopf Ernshaw Stauffer V Gibson PJ Ascher-Svanum H Ramsey JL Comparing olanzapine and ziprasidone in the treatment of schizophrenia: A case study in modeling Journal of Medical Economics 2001, 4:179-192.
98. Kongsakon R Leelahanaj T Price N Birinyi-Strachan L Davey P Cost analysis of the treatment of schizophrenia in Thailand: A simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol J Med Assoc Thai 2005, 88:1267-1277. 16536115
99. Bell CM Urbach DR Ray JG Bayoumi A Rosen AB Greenberg D Neumann PJ Bias in published cost effectiveness studies: Systematic review BMJ 2006, 332:699-703. 1410902 16495332 10.1136/bmj.38737.607558.80
100. Fairman KA Curtiss FR It's Only a Pharmacoeconomic Model - Believe It or Not J Manag Care Pharm 2008, 14:83-85.
101. Schrover R Crowley S Neville A Cost-effectiveness analysis of risperidone long acting injection (Risperdal Consta®) for the treatment of patients with schizophrenia who are partially medication adherent in Australia [abstract] Medical Decision Making 2006, 26:E67.
102. Vera-Llonch M Delea TE Richardson E Rupnow M Grogg A Oster G Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: A Markov model Value Health 2004, 7:569-584. 10.1111/j.1524-4733.2004.75008.x 15367252
103. Bounthavong M Okamoto MP Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia J Eval Clin Pract 2007, 13:453-460. 10.1111/ j.1365-2753.2006.00782.x 17518814
104. Daumit GL Goff DC Meyer JM Davis VG Nasrallah HA McEvoy JP Rosenheck R Davis SM Hsiao JK Stroup TS Lieberman JA Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study Schizophr Res 2008, 105:175-187. 10.1016/j.schres.2008.07.006 18775645
105. Nasrallah HA Meyer JM Goff DC McEvoy JP Davis SM Stroup TS Lieberman JA Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline Schizophr Res 2006, 86:15-22. 10.1016/j.schres.2006.06.026 16884895
106. Leucht S Corves C Arbter D Engel RR Li C Davis JM Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis Lancet 2009, 373:31-41. 10.1016/S0140-6736(08)61764-X 19058842